Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours

•Systematic evaluation of CDK4/6 as a target in 16 paediatric cancer types.•Outcomes are visualised in a publicly available interactive heatmap matrix.•Preclinical data on CDK4/6 as a target in paediatric cancer is relatively scarce.•Results provide the most support for CDK4/6 inhibition in Ewing sarcoma, medulloblastoma and malignant peripheral nerve sheath tumour.•Patients with neuroblastoma, rhabdomyosarcoma, atypical rhabdoid tumour/malignant rhabdoid tumour or high-grade glioma may benefit from CDK4/6 therapy too.